scholarly journals Progression of neuropsychiatric symptoms in pre‐dementia GRN and C9orf72 mutation carriers

2021 ◽  
Vol 17 (S6) ◽  
Author(s):  
Atri Chatterjee ◽  
Hyunwoo Lee ◽  
Ian R Mackenzie ◽  
Dana Wittenberg ◽  
Rosa Rademakers ◽  
...  
2021 ◽  
Vol 99 ◽  
pp. 1-10
Author(s):  
Rebecca E. Waugh ◽  
Laura E. Danielian ◽  
Rachel F. Smallwood Shoukry ◽  
Mary Kay Floeter

2016 ◽  
Vol 12 ◽  
pp. P62-P62
Author(s):  
Lize C. Jiskoot ◽  
Serge A.R.B. Rombouts ◽  
Jessica L. Panman ◽  
Elise G.P. Dopper ◽  
Tom den Heijer ◽  
...  

2021 ◽  
pp. 102687
Author(s):  
Karteek Popuri ◽  
Mirza Faisal Beg ◽  
Hyunwoo Lee ◽  
Rakesh Balachandar ◽  
Lei Wang ◽  
...  

2020 ◽  
Author(s):  
Rachel F. Smallwood Shoukry ◽  
Michael G Clark ◽  
Mary Kay Floeter

A repeat expansion mutation in the C9orf72 gene causes amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or symptoms of both, and has been associated with gray and white matter changes in brain MRI scans. We used graph theory to examine the network properties of brain function at rest in a population of mixed-phenotype C9orf72 mutation carriers (C9+). Twenty-five C9+ subjects (presymptomatic, or diagnosed with ALS, behavioral variant FTD (bvFTD), or both ALS and FTD) and twenty-six healthy controls underwent resting state fMRI. When comparing all C9+ subjects with healthy controls, both global and connection-specific decreases in resting state connectivity were observed, with no substantial reorganization of network hubs. However, when analyzing subgroups of the symptomatic C9+ patients, those with bvFTD (with and without comorbid ALS) show remarkable reorganization of hubs compared to patients with ALS alone (without bvFTD), indicating that subcortical regions become more connected in the network relative to other regions. Additionally, network connectivity measures of the right hippocampus and bilateral thalami increased with increasing scores on the Frontal Behavioral Inventory, indicative of worsening behavioral impairment. These results indicate that while C9orf72 mutation carriers across the ALS-FTD spectrum have global decreased resting state brain connectivity, phenotype-specific effects can also be observed at more local network levels.


2021 ◽  
Author(s):  
Ioanna Pachi ◽  
Christos Koros ◽  
Athina M Simitsi ◽  
Dimitra Papadimitriou ◽  
Anastasia Bougea ◽  
...  

Introduction: Higher prevalence of motor and non-motor features has been observed in non-manifesting mutation carriers of Parkinson s Disease (PD) compared to Healthy Controls (HC). The aim was to detect the differences between GBA and LRRK2 mutation carriers without PD and HC on neuropsychiatric symptoms. Methods: This is a cross-sectional retrospective study of non-manifesting GBA and LRRK2 mutation carriers and HC enrolled into Parkinsons Progression Markers Initiative (PPMI). Data extracted from the PPMI database contained: demographics and performance in MoCA scale and MDS-UPDRS scale part 1A (neuropsychiatric symptoms). All six features were treated as both continuous (MDS-UPDRS individual scores) and categorical variables (MDS-UPDRS individual score>0 and MDS-UPDRS individual score=0). Logistic regression analyses were applied to evaluate the association between mutation carrying status and neuropsychiatric symptoms. Results: In this study, the neuropsychiatric evaluation was performed in 285 GBA non-manifesting carriers, 369 LRRK2 non-manifesting carriers and 195 HC. We found that GBA non-manifesting mutation carriers were 2.6 times more likely to present apathy compared to HC, even after adjustment for covariates (adjusted OR=2.6, 95% CI=1.1-6.3, p=0.031). The higher percentage of apathy for LRRK2 carriers compared to HC was marginally non-significant. Other neuropsychiatric symptoms, such as psychotic or depressive manifestations, did not differ between groups. Conclusion: Symptoms of apathy could be present in the prediagnostic period of non-manifesting mutation carriers, especially, GBA. Longitudinal data, including detailed neuropsychiatric evaluation and neuroimaging, would be essential to further investigate the pathophysiological basis of this finding


2015 ◽  
Vol 130 (6) ◽  
pp. 845-861 ◽  
Author(s):  
Ian R. A. Mackenzie ◽  
Petra Frick ◽  
Friedrich A. Grässer ◽  
Tania F. Gendron ◽  
Leonard Petrucelli ◽  
...  

2020 ◽  
Vol 91 (9) ◽  
pp. 975-984 ◽  
Author(s):  
Tamara Paulo Tavares ◽  
Derek G V Mitchell ◽  
Kristy KL Coleman ◽  
Brenda L Coleman ◽  
Christen L Shoesmith ◽  
...  

ObjectivesThe clinical heterogeneity of frontotemporal dementia (FTD) complicates identification of biomarkers for clinical trials that may be sensitive during the prediagnostic stage. It is not known whether cognitive or behavioural changes during the preclinical period are predictive of genetic status or conversion to clinical FTD. The first objective was to evaluate the most frequent initial symptoms in patients with genetic FTD. The second objective was to evaluate whether preclinical mutation carriers demonstrate unique FTD-related symptoms relative to familial mutation non-carriers.MethodsThe current study used data from the Genetic Frontotemporal Dementia Initiative multicentre cohort study collected between 2012 and 2018. Participants included symptomatic carriers (n=185) of a pathogenic mutation in chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN) or microtubule-associated protein tau (MAPT) and their first-degree biological family members (n=588). Symptom endorsement was documented using informant and clinician-rated scales.ResultsThe most frequently endorsed initial symptoms among symptomatic patients were apathy (23%), disinhibition (18%), memory impairments (12%), decreased fluency (8%) and impaired articulation (5%). Predominant first symptoms were usually discordant between family members. Relative to biologically related non-carriers, preclinical MAPT carriers endorsed worse mood and sleep symptoms, and C9orf72 carriers endorsed marginally greater abnormal behaviours. Preclinical GRN carriers endorsed less mood symptoms compared with non-carriers, and worse everyday skills.ConclusionPreclinical mutation carriers exhibited neuropsychiatric symptoms compared with non-carriers that may be considered as future clinical trial outcomes. Given the heterogeneity in symptoms, the detection of clinical transition to symptomatic FTD may be best captured by composite indices integrating the most common initial symptoms for each genetic group.


2019 ◽  
Vol 86 (2) ◽  
pp. 158-167 ◽  
Author(s):  
Giorgia Querin ◽  
Peter Bede ◽  
Mohamed Mounir El Mendili ◽  
Menghan Li ◽  
Mélanie Pélégrini‐Issac ◽  
...  

2016 ◽  
Vol 12 ◽  
pp. P336-P337
Author(s):  
Lize C. Jiskoot ◽  
Serge A.R.B. Rombouts ◽  
Jessica L. Panman ◽  
Elise G.P. Dopper ◽  
Tom den Heijer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document